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Vibrio cholerae, the causative agent of cholera, is a
Gram-negative motile bacterial species acquired via
ingestion of contaminated food or water. Little is
known regarding the environmental survival factors
that exist in V. cholerae and play an important role in
maximizing the ability of the vibrios to survive and
multiply in the environment interacting with predators.
In a recent study, we established that Caenor-
habditis elegans is useful as a model system for identi-
fying and assessing factors from V. cholerae other than
cholera toxin that may contribute to pathogenesis and
damage to host organisms [1]. Using reverse molecular
genetics techniques, we identiﬁed an extracellular
protease, the previously uncharacterized PrtV protein,
as being necessary for killing of nematodes by
V. cholerae [1]. The killing effect is associated with col-
onization of the C. elegans intestine. The elucidation
of mechanisms behind this role for PrtV is of impor-
tance for the further understanding of V. cholerae
environmental survival and bacteria–host interaction.
Tissue barriers to pathogen invasion, such as extra-
cellular matrices, epidermal keratinocyte layers and
blood vessel walls, may be targeted by bacterial prote-
ases. Proteolysis of host tissue components, such as
extracellular matrix proteins, including collagen, lami-
nin, ﬁbronectin and elastin, could induce necrotic
tissue damage [2,3]. Pseudomonas aeruginosa and
Serratia mercescens proteases can degrade corneal pro-
teoglycan ground substance and cause keratitis [4,5].
The blood clotting system plays a role in immobiliza-
tion of invading pathogens and prevention of their dis-
semination. A pathogen can either use an arsenal of
its own proteases, or induce the host ﬁbrinolytic sys-
tem(s) to dissolve the ﬁbrin clot [6]. Yersinia pestis, the
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The Vibrio metalloprotease PrtV was puriﬁed from the culture supernatant
of a Vibrio cholerae derivative that is deﬁcient in several other secreted pep-
tidases, including the otherwise abundant hemagglutinin⁄protease HapA.
The PrtV is synthesized as a 102 kDa protein, but undergoes several
N- and C-terminal processing steps during V. cholerae envelope transloca-
tion and prolonged incubation. Puriﬁed V. cholerae PrtV protease forms of
81 or 73 kDa were stabilized by calcium ions. Removal of calcium resulted
in further rapid autoproteolysis. The two major products of autoproteolysis
of the PrtV protease were approximately 37 and 18 kDa and could not be
separated under non-denaturing conditions, indicating they are interacting
domains. In an assay using cultured cells of the human intestinal cell line
HCT8, the PrtV protein showed a cytotoxic effect leading to cell death.
Using human blood plasma as a source of potential substrates of mamma-
lian origin for the PrtV protease, we found that the extracellular matrix
components ﬁbronectin and ﬁbrinogen were degraded by the enzyme. Addi-
tional tests with individual protein substrates revealed that plasminogen
was also a possible target for the PrtV protease.
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activator Pla, whose inactivation decreases the infectiv-
ity of the bacterium a million-fold in a mouse infection
model in which the pathogen is injected subcutane-
ously, mimicking a ﬂea bite [7]. In some cases, bacte-
rial proteases act directly as toxins responsible for the
disease. Clostridial neurotoxins are zinc metallopro-
teases that speciﬁcally cleave a membrane protein of
synaptic vesicles, called synaptobrevin. Synaptobrevin
proteolysis prevents neurotransmitter release, which
results in paralysis of the host [8].
Pathogen-produced proteases may modulate bacte-
rial virulence factor activities, for example hemag-
glutinin⁄protease (as well as other proteases, including
those of the host) is able to process and activate
cholera toxin and hemolysin from V. cholerae [9,10].
The PrtV protease from V. cholerae belongs to the
evolutionary peptidase clan M6, and shares 37% iden-
tity with immune inhibitor A (InhA) from the Gram-
positive bacterium Bacillus thuringiensis [11]. InhA was
identiﬁed as one of extracellular bacterial factors that
can block the humoral defence system of pupae of the
silk moth Hyalophora cecropia against Escherichia coli,
but not against Bacillus subtilis or Bacillus cereus
[12,13]. Injection of puriﬁed InhA into Callosamia-
promethea pupae and Drosophila melanogaster caused
lethality [13]. The puriﬁed InhA preparation showed
weak proteolytic activity on casein, but was more
active in degrading antimicrobial peptides from the
hemolymph of Hyalophora cecropia in vitro [14]. A
study of the speciﬁcity of the enzyme towards a syn-
thetic and a natural cecropin antimicrobial peptide did
not identify any distinct pattern, as a number of
peptide bonds were cleaved [14] (http://merops.
sanger.ac.uk/). It was therefore concluded that the pro-
teolytic attack may be of broad speciﬁcity because
cecropins occur largely in a random coil conformation
in solution, and this open structure made them suscep-
tible to the InhA protease [15]. As degradation of
inducible antimicrobial peptides is not likely to cause
lethality to insects, other unidentiﬁed targets of InhA
were suggested [15]. In addition, InhA1, a homologue
of InhA, was shown to be required for lethal oral
B. thuringiensis infection of insect larvae [16,17]. The
M6 evolutionary protein family has been found to be
distributed in various species of environmental bacteria
including Vibrio, Shewanella, Clostridium, Geobacillus
and Bacillus, suggesting that there might be a role for
this type of protease in bacterial environmental persis-
tance and survival [18] (http://merops.sanger.ac.uk/).
The V. cholerae PrtV protein is postulated to share
certain properties with the well-studied proteases
from Bacillus species, such as the presence of a
Zn
2+-binding site and modulation of activity⁄stability
by divalent metal ions. However, the actual substrate
speciﬁcity of the PrtV protein from V. cholerae has not
been elucidated, and no puriﬁcation and characteriza-
tion were performed for this M6 peptidase from Vibrio
or any other Gram-negative bacterial species. A simi-
larly named protease (designated PrtVp or PrtV) has
been described and puriﬁed from Vibrio parahemolyti-
cus [19–21]. However, the PrtVp enzyme is a collage-
nase, lacks homology to PrtV of V. cholerae, and
belongs to a separate metalloprotease evolutionary
family, M9 (http://merops.sanger.ac.uk/). In addition,
there are two putative M6 family protease encoding
genes in the published genome sequence of V. parahe-
molyticus RIMD2210633 (the genetic loci VP0907 and
VPA0715 are both separate from the PrtVp locus), but
none of their gene products have yet been character-
ized (http://www.ncbi.nlm.nih.gov/sites/entrez).
In this study, the PrtV protein of V. cholerae O1
strain C6706 was puriﬁed and assayed for its proteo-
lytic activities using azocasein, gelatin and human
plasma proteins as substrates, and tested in a cytotox-
icity assay using human ileocaecum carcinoma cells
(HCT8 cell line).
Results and Discussion
Puriﬁcation and physicochemical characterization
of the PrtV protein from V. cholerae
PrtV is encoded by a 102 kDa ORF [11], is secreted
from V. cholerae cells, and undergoes several N- and
C-terminal (auto)proteolytic cleavage steps resulting
in active protease forms of 81 and 73 kDa (lane 6 in
Fig. 1A). Optimized expression of PrtV was induced
using 0.002% arabinose, and puriﬁcation was per-
formed as described in Experimental procedures. This
protein preparation resulted in enrichment of the 81
and 73 kDa PrtV protease forms (Fig. 1). The 15 L
of culture supernatant yielded approximately 50 mg
of total PrtV protein preparation, with > 90% being
the 81 kDa protein form. Mass spectrometric analysis
of the 81 and 73 kDa derivatives of the PrtV protein
veriﬁed the presence of amino acids 137–834 and
137–763 of the full-length protein, respectively. Fur-
ther N-terminal sequence analysis showed that these
protein forms start with amino acid 106 (numbers
refer to positions in the full-length PrtV protein). The
81 kDa protein contained the intact sequence of one
of two polycystic kidney disease (PKD) domains at
the C-terminus (Fig. 1C) [18,22] (http://merops.
sanger.ac.uk/; http://pfam.sanger.ac.uk/), but neither
of these domains were present in the 73 kDa form of
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known; it may be involved in protein–protein or pro-
tein–carbohydrate interactions and is found in some
bacterial proteases and chitinases, as well as arche-
bacterial and vertebrate proteins [22] (http://pfam.
sanger.ac.uk/). These major PrtV fragments were
partially separated by ion-exchange chromatography;
however, further degradation of both enzyme forms
occurred, resulting in the gradual accumulation of
lower-molecular-mass autoproteolysis products (lanes
9 and 10 in Fig. 2).
Optimum conditions for the stability and
processing of the PrtV protein
The enzyme was relatively stable at low temperature
in the presence of Ca
2+ ions; however, it could be
further degraded, eventually resulting in two inter-
acting polypeptide chains of 37 and 18 kDa (Figs 1B
and 2). A similar conversion has been described for
immune inhibitor A from Bacillus anthracis and
B. cereus [23,24]. Mass-spectrometric analysis of tryp-
tic digestion products showed that the 37 kDa N-ter-
minal part of the PrtV protease contains amino acids
137–425, which include the predicted catalytic Zn
2+
binding site. N- and C-terminal sequencing conﬁrmed
these ﬁndings, and the precise terminal amino acids
of the 37 kDa PrtV fragment were found to be 106
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Fig. 1. V. cholerae PrtV puriﬁcation steps, calcium requirement for
stability, and autoprocessing. (A) PrtV puriﬁcation steps. Samples
taken at various stages during the protein puriﬁcation were analy-
sed by SDS–PAGE and Coomassie blue staining. Lane 1, culture
supernatant proteins concentrated 40-fold by trichloroacetic acid
precipitation; lane 2, permeate after ultraﬁltration and 40-fold con-
centration of proteins by trichloroacetic acid precipitation; lane 3,
retentate after ultraﬁltration; lane 4, pellet after retentate centrifuga-
tion; lane 5, supernatant after retentate centrifugation; lane 6, PrtV
preparation after chromatography on a DEAE-Toyopearl 650S col-
umn; M, prestained molecular mass marker, molecular masses indi-
cated in kDa. (B) Calcium requirement for PrtV protease stability.
The PrtV fraction consisting mainly of the 81 kDa form of the prote-
ase (amino acids 106–834) was desalted on a Sephadex G25
HiPrep 26⁄10 column (GE Healthcare, Chalfont St Giles, UK) equili-
brated with a buffering solution containing 10 mM MgCl2. Exchange
of calcium with magnesium led to destabilization of the PrtV metal-
loprotease and autoproteolysis, resulting in stable PrtV peptide
chains marked 37 kDa (amino acids 106–434) and 18 kDa (amino
acids 587–749). The estimated molecular masses of PrtV fragments
were calculated from mass spectrometry data of the tryptic diges-
tion products combined with the N- and C-terminal sequencing data
(see Results). Lane 1, PrtV fraction after chromatography on a
DEAE-Toyopearl 650S column containing 10 mM CaCl2; lane 2, PrtV
fraction for which Ca
2+ has been exchanged with Mg
2+ as described
above and incubated for 3 h on ice; lane 3, PrtV fraction for which
Ca
2+ has been exchanged with Mg
2+and incubated for 1 h at 30  C;
lane 4, PrtV fraction for which Ca
2+ has been exchanged with
Mg
2+and incubated for 2 h at 30  C; lane 5, PrtV fraction for which
Ca
2+ has been exchanged with Mg
2+and incubated for 3 h at 30  C;
M, prestained molecular mass markers indicated in kDa. (C) Sche-
matic representation of PrtV protein forms identiﬁed in this study.
The M6 peptidase domain, its predicted catalytic Zn
2+-binding site
and PKD domains are indicated with respect to the 918 amino acid
full-length PrtV protein. The lower diagrams show the 81, 73, 37
and 18 kDa processed forms of the PrtV protease with terminal
amino acid residues indicated by numbers (referring to positions in
the full-length PrtV protein). In the case of the 18 kDa polypeptide,
the numbers are shown in parentheses as they represent tentative
termini deduced from mass spectrometry analysis.
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PrtV protein). The 18 kDa C-terminal part contains
amino acids 587–749 of the full-length PrtV protein
(Fig. 1C) as determined by mass spectrometry of the
tryptic digest products; N- and C-terminal sequencing
attempts on the 18 kDa form were unsuccessful. The
molecular masses of the PrtV protease fragments were
calculated assuming the length of these proteins to be
as detected by mass spectrometry of tryptic digestion
products and combined with the data from N- and
C-terminal sequencing. Separation of the 37 and
18 kDa PrtV polypeptides using size-exclusion, anion-
exchange and hydrophobic-interaction chromato-
graphy were unsuccessful (data not shown). The
resulting protein migrated as a band of approximately
55 kDa by SDS–PAGE if it had not been heat-dena-
tured (compare lanes 3, 4, 7 and 8 with lanes 11 and
12 in Fig. 2). The proteolytic activity for tested sub-
strates of the 55 kDa form of PrtV was identical to
that of the 81 or 73 kDa forms (data not shown and
Fig. 2). However, the 81 kDa form was gradually
converted to the 73 kDa PrtV form during incubation
with substrates even in the presence of 10 mm Ca
2+
(data not shown). The molar activity ratio of 55 and
73 kDa PrtV forms was estimated to be 1.12 ± 0.07
using a ﬂuorescein-labelled gelatin substrate, and
therefore there is probably no difference in the spe-
ciﬁc activity of these two protease forms. Therefore,
the 55 kDa PrtV form (37 + 18 kDa) that remains
stable in the absence of Ca
2+ was used for further
PrtV characterization.
The PrtV protein was stabilized by the addition of
Ca
2+, although excess addition of this ion was not
essential for enzyme activity (Figs 1B and 3). PrtV
activity was enhanced by Ca
2+ ,S r
2+ ,M g
2+ and to
some extent Ba
2+ ; however, Ba
2+ inhibited PrtV at
higher concentrations whereas the other divalent
metal ions tested showed an enhancement of PrtV
proteolytic activity (Fig. 3A). The optimal concentra-
tion of Ca
2+ ,S r
2+ and Mg
2+ was approximately
25 mm, and the highest activity of PrtV occurred in
the presence of Sr
2+ (Fig. 3A). An enhancement of
proteolytic activity was observed by the addition of
monovalent metal ion Na
+ ,K
+ and Li
+ salts
(Fig. 3B), as has also been demonstrated for some
other metalloenzymes, e.g. a collagenase from
Clostridium histolyticum [25], thermolysin [26], and a
metallopeptidase from Lactobacillus helveticus [27].
The optimal LiCl salt concentration for PrtV proteo-
lytic activity was 0.2 m, but the activity was enhanced
in the presence of NaCl or KCl at concentrations of
up to 0.5 m (Fig. 3B).
No activity of PrtV was detected using the synthetic
neutral proteinase substrate FAGLA and collagenase
substrate FALGPA (data not shown).
Inhibition of PrtV activity
The metal ion chelators EDTA and 1,10-phenan-
throline completely inhibited the PrtV protease, and
the activity could not be restored by addition of excess
calcium ions (Fig. 3C). Addition of excess calcium
increased the concentration of EDTA required for
inhibition of PrtV protease activity, but 1,10-phenan-
throline, which does not chelate calcium ions, was
equally efﬁcient at inhibiting the protease with or with-
out Ca
2+ . A metalloprotease inhibitor galardin [28]
inhibited the PrtV protease at a 200–20 000-fold molar
excess (Fig. 3C).
Cytotoxic activity of PrtV
To test possible toxic activities of PrtV towards mam-
malian tissue, puriﬁed enzyme was added to cultured
human colon cancer HCT8 cells. The cytotoxic effect
of the PrtV protein, as observed by ﬂuorescence
1 4 3 2 89 10 11 12 M 567
kD
72
55
95
130
170
73 kDa 
kDa
55
43
30
37 kDa 
55 kDa 
26
18 kDa 
17
11
A B
Fig. 2. Interaction between the two main PrtV autoproteolysis
products. Samples in lanes 1-4 were analyzed by zymography on
an SDS–PAGE gel containing gelatin as a PrtV substrate. SDS–
PAGE was performed for both unboiled and boiled PrtV samples
(lanes 1-8 and 9-12, respectively). Lanes 3, 4, 7, 8, 11 and 12 were
loaded with PrtV protease destabilized by exchange of soluble cal-
cium with magnesium, which resulted in 37 and 18 kDa protein
fragments (as determined by mass spectrometry of tryptic diges-
tion products, and N- and C-terminal peptide sequencing) further
co-puriﬁed on a HiLoad 16⁄60 Superdex 75 pg chromatography col-
umn (GE Healthcare). Lanes 1, 2, 5, 6, 9 and 10 were loaded with
the PrtV protein fraction consisting of mostly the 73 kDa protein
fragment (amino acids 106–763). The protein amount in lanes 1, 3,
5, 7, 9 and 11 is 15 pmol and that in lanes 2, 4, 6, 8, 10 and 12 is
5 pmol. The lane marked M contains a prestained molecular mass
marker (molecular masses indicated in kDa). Proteins in gels were
stained using Coomassie blue.
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HCT8 cells with 0, 5, 10 and 50 nm of puriﬁed PrtV.
As shown in Fig. 4, the degree of cytotoxicity was
increased by the amount of PrtV added to the cells,
indicating that cytotoxicity of PrtV was dose-depen-
dent. This result suggests that the PrtV protein of
V. cholerae, similar to other proteases [2] including
hemagglutinin⁄protease from V. cholerae [29], might
cause tissue damage by directly degrading substrate
proteins in host tissues, thereby inducing cell round-
ing and detachment.
Substrate speciﬁcities of PrtV as monitored with
human plasma proteins
To study potential targets of the PrtV protein, we
initially used human serum as a source of substrate
proteins to deﬁne the speciﬁcity of the enzyme. Candi-
date substrates for this enzyme were determined by
mass spectrometry after comparing plasma protein pat-
terns using SDS–PAGE following incubation with and
without PrtV (Fig. 5). The blood plasma components
analyzed using this method were as follows: (a) lipo-
protein⁄apolipoprotein, (b) ﬁbronectin-1, (c) a-2-mac-
roglobulin, (d) complement component C3, (e) ﬁbrin
b chain, (f) not identiﬁed, (g) a-2-macroglobulin, (h)
a-2-macroglobulin mixture with PrtV, (i) a-1-antitryp-
sin, (j) complement component C3 and ﬁbrinogen, and
(k) ﬁbrinogen (Fig. 5). Potential candidates and several
other human plasma proteins were selected for conﬁr-
mation of direct cleavage and degradation by the PrtV
protease using pure candidate substrates. Fibrinogen
(all a, b and c chains), ﬁbronectin and plasminogen
were effectively degraded (Fig. 6). Immunoglobulin A,
immunoglobulin G, urokinase-type plasminogen acti-
vator and thrombin were not affected by incubation
with PrtV (Fig. 7A–C,F). a-2-macroglobulin most
likely underwent an activation step [30] induced by the
protease, resulting in the appearance of a 85 kDa band
on an SDS–PAGE gel after incubation with the PrtV
protease (Fig. 7D). Limited cleavage of the C3 comple-
ment component probably occurred in the a chain
(Fig. 7E). Taken together, the results from the human
blood plasma experiments and conﬁrmation of proteo-
lytic cleavage with puriﬁed candidate substrates show
that ﬁbrinogen, ﬁbronectin and plasminogen are
among the preferred substrates of PrtV.
Plasminogen, the zymogen of the ﬁbrinolytic sys-
tem, is converted into the active enzyme plasmin by
plasminogen activators [31]. Plasmin(ogen) not only
plays an essential role in the clearance of ﬁbrin from
the circulation, but also is involved in several other
biological phenomena, including macrophage recruit-
ment, arterial stenosis, atherosclerosis, aneurysm for-
mation, skin and corneal wound healing,
glomerulonephritis and neovascularization [32–35].
SDS–PAGE analysis of the human plasminogen⁄PrtV
protein reaction mixtures revealed that the majority of
native plasminogen was converted to lower-molecular-
mass fragments. To study the interaction of PrtV pro-
tease with plasminogen in more detail, the time course
of proteolysis was analyzed at various time points. As
shown in Fig. 6D, 50% degradation of plasminogen
was observed within 60 min at 0.4 mgÆmL
)1 substrate
and 100 nm PrtV concentrations, whereas about 80%
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terization of the generated plasminogen fragments by
puriﬁcation and functional characterization is neces-
sary to explain the mechanism of PrtV protein proteo-
lytic activity on human plasminogen. Taken together,
we suggest that the PrtV protease of V. cholerae
might play a role in V. cholerae pathogenesis by mod-
ulation of the stability of the extracellular matrix in
host tissues.
The range of primary sequences that constitute actual
cleavage sites for the PrtV enzyme remains to be deter-
mined. Examination of the PrtV amino acid sequences
representing cleavage positions in PrtV autoproteolysis,
as determined by N- and C-terminal sequencing, pro-
vided initial information to be explored in future studies.
For example, the ends of the 81, 73 and 37 kDa poly-
peptides reveal that cleavage may occur at the following
amino acid sequences: RVF⁄ALD, RVE⁄GIK and
TIK⁄VDT. Such sequences were indeed found to be
present in human complement components and immu-
noglobulins according to our BLAST database searches
(data not shown), but further studies are required
to determine which ﬂanking amino acids are parts of
cleavage sites. The present studies and puriﬁcation of
PrtV should aid further biochemical analyses.
We hypothesize that, in the case of V. cholerae, this
PrtV protease and its gene, located in a putative
pathogenicity island in the second chromosome, some-
how contribute to bacterial survival in natural envi-
ronments, i.e. in contact with natural host organisms,
such as protozoa, copepods and crustaceans. The sub-
strates of the protease in vivo remain unknown. Given
the activity of the protease on human extracellular
matrix proteins and blood components, the present
ﬁndings suggest that PrtV could interfere with normal
extracellular matrix composition, hemostasis and
innate immune responses in intestinal or wound inf-
ections.
Experimental procedures
Puriﬁcation of the PrtV protein
The secreted PrtV metalloprotease was puriﬁed from 15 L
of culture supernatant from the V. cholerae strain KAS202
carrying plasmid pKVA232 harboring a full-length prtV
gene under the control of an arabinose-inducible promoter
[1]. TG culture medium [36] supplemented with 5 mm
CaCl2, 0.5% w⁄v casamino acids (Becton Dickinson,
Franklin Lakes, NJ, USA), 50 lgÆmL
)1 l-tryptophan and
50 lgÆmL
)1 carbenicillin was used for bacterial growth.
Protein expression was induced by addition of 0.002%
w⁄v l-arabinose when the cell density reached an attenu-
ance (D600) of 0.5. After 14 h incubation at 30  Co na
rotary shaker at 100 rpm in Ehrlenmeyer ﬂasks, the bacte-
rial cells were removed by centrifugation at 5000 g for
A B
C D
Fig. 4. Cytotoxic effect of puriﬁed PrtV pro-
tein of V. cholerae on HCT8 cells. (A) Con-
trol without PrtV protein; (B)–(D) HCT8 cells
treated with 5 nM (B), 10 nM (C) or 50 nM
(D) PrtV protein. After 6 h treatment, actin
ﬁlaments and nuclei were stained with phal-
loidin and DAPI, respectively, as described
in Experimental procedures.
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were clariﬁed by depth ﬁltration through LP50- and LP90-
grade Zeta Plus ﬁltration media (CUNO, Meriden, CT,
USA). The ﬁltrates were concentrated 30-fold, and the sol-
ute exchanged with a buffering solution compatible with a
further puriﬁcation step using a Prep⁄Scale 0.23 m
2
30 kDa cut-off polysulfone membrane cartridge (Millipore,
Billerica, MA, USA). The retentate after ultraﬁltration
was centrifuged for 30 min at 20 000 g, and the superna-
tants were ﬁltered through a 0.22 lm pore diameter poly-
sulfone membrane (Millipore) and applied onto a 65 mL
Toyopearl DEAE 650S column (Tosoh, Tokyo, Japan).
The PrtV protease was eluted using a linear NaCl gradient
from 0 to 180 mm. All steps were carried out in a buffer
solution containing 10 mm CaCl2 to stabilize the enzyme,
20 mm triethanolamine pH 7.80 as a buffering agent, and
1-5 mm dithiothreitol as an antioxidant. Fractions contain-
ing PrtV were desalted on a 53 mL Sephadex G25 column
(GE Healthcare) and frozen in a dry ice⁄ethanol bath.
Selected fractions containing PrtV protein were further
puriﬁed by chromatography using a 1 mL MonoQ column
(GE Healthcare) by gradient elution with NaCl. The pro-
tein concentration was determined by light absorbance at
280 nm.
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Fig. 5. Human blood plasma proteins as candidate substrates for
the PrtV protease. The letters ‘a’–‘k’ indicate protein bands excised
from the SDS–PAGE gel for protein identiﬁcation by mass spectro-
metric analysis. Lanes 1 and 2 were loaded with blood plasma pro-
teins incubated with PrtV for 5 and 120 min respectively, while
lane 3 contained blood plasma proteins incubated for 120 min with-
out the protease under the same conditions. M, prestained mole-
cular mass marker (molecular masses indicated in kDa).
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Fig. 6. Proteolysis of ﬁbrinogen (A), ﬁbronectin (B) and plasmino-
gen (C) by PrtV. Lane M, molecular mass markers indicated in kDa;
lanes 1 and 8, pure candidate substrate protein without PrtV; lanes
2–7, candidate substrate protein incubated with PrtV protease as
described in Experimental procedures. The time points for samples
taken during incubation at 37  C were: lane 1, 0 min; lane 2, 1 min;
lane 3, 5 min; lane 4, 15 min; lane 5, 30 min; lane 6, 60 min; lanes
7 and 8, 120 min. The quantiﬁcation of plasminogen remaining
intact at various time points is shown in (D).
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A modiﬁed azocasein assay was used for routine activity
measurements as described previously [1]. A more sensitive
and linear method using ﬂuorescein-labeled gelatin
(DQ Gelatin; Molecular Probes, Eugene, OR, USA) was
used for conﬁrmation of data obtained with the azocasein
substrate (Sigma, St Louis, MO, USA). DQ Gelatin
(12.5 lgÆmL
)1) was incubated at 37  C with 5 nm PrtV pro-
tease in 50 mm Hepes pH 7.20 unless speciﬁed otherwise.
The reaction rate was measured at 495 nm excitation and
535 emission wavelengths using 96-well black non-binding
surface microplates (Corning, NY, USA). Measurements
were performed on an Inﬁnite M200 ﬂuorescence micro-
plate reader (Tecan, Mannedorf, Switzerland). The activity
of the protease was tested on synthetic peptide substrates
FAGLA (3-(2-furylacryloyl)-glycyl-l-leucine amide) and
FALGPA (2-furylacryloyl-l-leucylglycyl-l-prolyl-l-alanine)
using previously described procedures [35,37].
Where applicable, reagent solutions were dithizone-
extracted [38] for adventitious metal ion control.
Zymography
Detection of proteolytic activity was performed by
SDS–PAGE using 0.25% w⁄v gelatin as a substrate in the
separating gel. Protein samples in SDS–PAGE sample buf-
fer were incubated for 5 min at 37  C before loading. After
electrophoresis, SDS was washed out from the gel by soak-
ing for 30 min in 20% 2-propanol [39], 50 mm Tris⁄Cl
pH 7.50 and 10 mm CaCl2, exchanging the solution every
10 min. Renaturation of proteins in the gel was performed
by incubation in 50 mm Tris⁄Cl pH 7.50, 10 mm CaCl2 and
5% glycerol at 4  C for 4 h. Proteolysis was allowed to
occur for 1–24 h at 37  C in the same solution, although
PrtV activity was readily detected after incubation at 4  C.
After Coomassie blue staining, areas of protease activity in
the gel appeared as clear bands where the protease had
digested the gelatin, against a dark blue background.
Analysis of substrate proteins in blood plasma
by the PrtV protease
Human blood plasma was used to analyze potential sub-
strate proteins of the PrtV protein of V. cholerae. Blood
plasma was diluted 100-fold in 50 mm Tris⁄Cl pH 7.50 and
10 mm MgCl2. Subsequently, 10 lgÆmL
)1 (129 nm) of the
81 kDa PrtV protease was added and the mixture was incu-
bated at 37  C. At various time intervals, a portion of the
reaction solution was removed and analysed by SDS–
PAGE and Coomassie blue staining. The degraded proteins
bands were excised from the gel and identiﬁed by mass
spectrometric analysis of tryptic digestion products.
Substrate speciﬁcity assay
Tests of substrate speciﬁcity of the PrtV protein were
performed using commercially available puriﬁed human
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Fig. 7. Testing of IgA (A), IgG (B), urokinase-type plasminogen acti-
vator (C), a-2-macroglobulin (D), complement component C3 (E)
and thrombin (F) for PrtV proteolysis. Lane M, molecular mass
markers indicated in kDa; lanes 1 and 8, pure candidate substrate
protein without PrtV; lanes 2–7, candidate substrate protein incu-
bated with PrtV protease as described in Experimental procedures.
The time points for samples taken during incubation at 37  C were:
lane 1, 0 min; lane 2, 1 min; lane 3, 5 min; lane 4, 15 min; lane 5,
30 min; lane 6, 60 min; lanes 7 and 8, 120 min.
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globulin A, immunoglobulin G, ﬁbrinogen, ﬁbronectin,
plasminogen, urokinase-type plasminogen activator and
thrombin. Candidate substrate proteins of the PrtV prote-
ase at a concentration of 0.4 mgÆmL
)1 in 50 mm HEPES
pH 7.20, 1 mm CaCl2 and 1 mm MgCl2 were assayed for
cleavage by 100 nm PrtV protein (37 + 18 kDa form). The
reaction was analysed by SDS–PAGE and Coomassie blue
staining at several time points during incubation at 37  C.
SDS–PAGE analysis
SDS–PAGE analysis was performed as described previously
[40]. When necessary, quantiﬁcation of Coomassie-stained
protein bands in gel was performed using quantity one
software (Bio-Rad, Hercules, CA, USA).
Protein identiﬁcation
Mass spectrometry, protein identiﬁcation and database
searches were carried out by the Wallenburg Consortium
north Expression Proteomics Facility (Department of Medi-
cal Biochemistry and Microbiology, Uppsala University,
Sweden). For the mass spectrometry analysis, proteins in
gel slices were alkylated with iodoacetamide and digested
using modiﬁed trypsin (Promega, Fitchburg, WI, USA).
The digests were analysed by MALDI-TOF mass spectros-
copy using an Ultraﬂex Tof⁄Tof instrument (Bruker
Daltonics, Bremen, Germany). The instrument was cali-
brated using peptide mixture II (Bruker Daltonics), and
each spectrum was calibrated using autodigestion products
of the trypsin. After removal of background peaks and cor-
rection of software errors in detecting monoisotopic m⁄z,
the peak lists were used to search the National Center for
Biotechnology Information non-redundant database using
the Mascot search engine (http://www.matrixscience.com).
For estimation of cleavage positions in the degraded forms
of the metalloprotease, the m⁄z of tryptic peptides was ﬁt-
ted to the amino acid sequence of the protease. N- and
C-terminal amino acid sequence analyses by Edman degra-
dation and C-terminal chemical degradation of the protein
bands identiﬁed as the 81, 73 and 55 kDa PrtV forms in
SDS–PAGE (see Results) were performed by the Protein
Analysis Center at the Karolinska Institute, Stockholm,
Sweden (http://www.mbb.ki.se/pac/index.html).
Protease inhibition analyses
The effects of the metalloprotease inhibitor galardin
(5 · 10
2 to 10
5 nm) and metal-chelating compounds EDTA
(10
2 to 2 · 10
6 nm) and 1,10-phenanthroline (5 · 10
2 to
10
5 nm) were examined by preincubation of the puriﬁed
PrtV protein (37 + 18 kDa form) at 5 nm concentration
for 30 min with one of inhibitors in 50 mm HEPES
pH 7.20, followed by addition of the DQ Gelatin (Molecu-
lar Probes) substrate and ﬂuorescence measurement using
an Inﬁnite M200 instrument (Tecan). The PrtV activity
with EDTA and 1,10-phenanthroline was measured both in
the presence and absence of 10 mm CaCl2.
Cell line, media and culture conditions
The human ileocecum carcinoma cell line HCT8 (ATCC
number CCL-224) was kindly provided by the Institute for
Molecular Infection Biology, University of Wu ¨ rzburg,
Germany.
HCT8 cells were cultured in RPMI-1640 (Invitrogen,
Carlsbad, CA, USA) supplemented with 2 mm glutamine,
1m m pyruvate, 10% fetal bovine serum and 50 lgÆmL
)1
gentamicin. The cells were cultivated at 37  C in a 5% CO2
atmosphere.
Tissue toxicity assay
HCT8 cells were seeded in 24-well plates (Becton Dickin-
son) and grown to 50% conﬂuence. Puriﬁed PrtV protein
(5–50 nm) was added to the cells. The occurrence of cyto-
toxic effects was monitored and compared with the
responses of control cells for up to 6 h. Cells were ﬁxed
with 2% paraformaldehyde in NaCl⁄Pi (pH 7.3) for 10 min.
After ﬁxation, cells were washed twice with NaCl⁄Pi and
incubated with 0.1 m glycine for 5 min at room tempera-
ture. After washing twice with NaCl⁄Pi, the cells were per-
meabilized with 0.5% Triton X-100 (Sigma-Aldrich). Actin
was stained using Alexa Fluor 488 phalloidin (Molecular
Probes) containing 1% BSA (Sigma-Aldrich). After thor-
ough washing with NaCl⁄Pi, the nuclei were stained with
DAPI (Sigma-Aldrich) (1 : 5000) for 5 min before mounting
in Mowiol (Scharlau Chemie SA, Barcelona, Spain) that
contains antifade (P-phenylene diamine). Cells were analy-
sed using a Zeiss Axioskop (Zeiss, Oberko ¨ chen, Germany)
microscope, and photographed using a Hamamatsu digital
camera (Hamamatsu, Hamamatsu City, Japan).
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